Sensorium Therapeutics is a clinical stage biotechnology company developing brain and mental health treatments that are derived from nature, mechanistically driven, clinically precise, and designed to help people thrive. Its proprietary SensAI™ platform integrates artificial intelligence, chemistry, and neuroscience to mine more than 50 million curated relationships across biology, pharmacology, clinical outcomes, and human experience to unlock broader and derisked starting points for CNS drug discovery. SensAI has produced three differentiated programs in under three years—led by SENS-01, a first-in-class treatment for anxiety—and built a robust IP estate extending into the 2040s.

The latest

‍Contact

‍News